首页 > 最新文献

Journal of Diabetes Investigation最新文献

英文 中文
Association of impaired fasting glucose with cardiometabolic multimorbidity: The Kailuan study 空腹血糖受损与心脏代谢多病性的关系:开滦研究
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-24 DOI: 10.1111/jdi.14316
Zhihui Guo, Shouling Wu, Mengyi Zheng, Pengfei Xia, Qiuyun Li, Qing He, Zhenqiang Song

Aims/Introduction

We investigated the association between impaired fasting glucose (IFG) and cardiometabolic multimorbidity (CMM) in the Chinese population.

Materials and Methods

We included 119,368 participants, free of diabetes mellitus and cardiovascular disease, who participated in the health examination (2006, 2008, 2010) of the Kailuan Study. According to World Health Organization diagnostic criteria, participants were divided into normal fasting blood glucose (FBG) (<6.1 mmol/L) and IFG (FBG 6.1–6.9 mmol/L) groups. CMM was defined as having two or more cardiometabolic diseases, including myocardial infarction, stroke and diabetes mellitus. We used Cox proportional hazards models to evaluate associations between IFG and CMM.

Results

During a median follow-up period of 13.94 years, 2,432 CMM incident events occurred. After adjusting potential confounders, the hazard ratio (HR) and 95% confidence interval (CI) for CMM in the IFG group was 2.83 (95% CI 2.58–3.10) versus the normal FBG group. The HR of IFG for diabetes mellitus was 3.43 (95% CI 3.30–3.55), which was >1.25 (95% CI 1.13–1.37) for myocardial infarction, 1.16 (95% CI 1.07–1.25) for ischemic stroke and 1.06 (95% CI 0.88–1.27) for hemorrhagic stroke. Compared with normal FBG, HRs for risk of IFG for CMM were 2.73 (95% CI 2.48–3.02) in men and 3.86 (95% CI 2.92–5.09) in women.

Conclusion

IFG was a risk factor for CMM. The effect of IFG on diabetes mellitus was stronger than that on other cardiometabolic diseases. The effects of IFG for CMM differed by sex.

目的/简介:我们研究了中国人群空腹血糖受损(IFG)与心脏代谢多病(CMM)之间的关系:我们纳入了参加开滦研究健康体检(2006年、2008年和2010年)的119368名无糖尿病和心血管疾病的参与者。根据世界卫生组织的诊断标准,参试者被分为空腹血糖(FBG)正常(结果:FBG正常的参试者中,空腹血糖正常的参试者中,空腹血糖异常的参试者中,空腹血糖异常的参试者中,空腹血糖异常的参试者中,空腹血糖异常的参试者中在13.94年的中位随访期内,共发生了2432例CMM事件。调整潜在混杂因素后,IFG 组与正常 FBG 组相比,CMM 的危险比(HR)和 95% 置信区间(CI)为 2.83(95% CI 2.58-3.10)。IFG组糖尿病的HR为3.43(95% CI 3.30-3.55),心肌梗死的HR>1.25(95% CI 1.13-1.37),缺血性卒中的HR为1.16(95% CI 1.07-1.25),出血性卒中的HR为1.06(95% CI 0.88-1.27)。与正常FBG相比,男性IFG导致CMM的风险HR为2.73(95% CI 2.48-3.02),女性为3.86(95% CI 2.92-5.09):结论:IFG是CMM的一个危险因素。结论:IFG是CMM的危险因素,IFG对糖尿病的影响强于对其他心血管代谢疾病的影响。IFG对CMM的影响因性别而异。
{"title":"Association of impaired fasting glucose with cardiometabolic multimorbidity: The Kailuan study","authors":"Zhihui Guo,&nbsp;Shouling Wu,&nbsp;Mengyi Zheng,&nbsp;Pengfei Xia,&nbsp;Qiuyun Li,&nbsp;Qing He,&nbsp;Zhenqiang Song","doi":"10.1111/jdi.14316","DOIUrl":"10.1111/jdi.14316","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>We investigated the association between impaired fasting glucose (IFG) and cardiometabolic multimorbidity (CMM) in the Chinese population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We included 119,368 participants, free of diabetes mellitus and cardiovascular disease, who participated in the health examination (2006, 2008, 2010) of the Kailuan Study. According to World Health Organization diagnostic criteria, participants were divided into normal fasting blood glucose (FBG) (&lt;6.1 mmol/L) and IFG (FBG 6.1–6.9 mmol/L) groups. CMM was defined as having two or more cardiometabolic diseases, including myocardial infarction, stroke and diabetes mellitus. We used Cox proportional hazards models to evaluate associations between IFG and CMM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During a median follow-up period of 13.94 years, 2,432 CMM incident events occurred. After adjusting potential confounders, the hazard ratio (HR) and 95% confidence interval (CI) for CMM in the IFG group was 2.83 (95% CI 2.58–3.10) versus the normal FBG group. The HR of IFG for diabetes mellitus was 3.43 (95% CI 3.30–3.55), which was &gt;1.25 (95% CI 1.13–1.37) for myocardial infarction, 1.16 (95% CI 1.07–1.25) for ischemic stroke and 1.06 (95% CI 0.88–1.27) for hemorrhagic stroke. Compared with normal FBG, HRs for risk of IFG for CMM were 2.73 (95% CI 2.48–3.02) in men and 3.86 (95% CI 2.92–5.09) in women.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>IFG was a risk factor for CMM. The effect of IFG on diabetes mellitus was stronger than that on other cardiometabolic diseases. The effects of IFG for CMM differed by sex.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"129-136"},"PeriodicalIF":3.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart rate variability indices for predicting cardiorenal outcomes: A lesson from the PERL and ACCORD cohorts 预测心衰预后的心率变异性指数:从 PERL 和 ACCORD 队列中汲取的教训。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-18 DOI: 10.1111/jdi.14333
Kazuhiro Sugimoto

This commentary highlights the role of heart rate variability (HRV) indices in predicting diabetic kidney disease (DKD) progression, based on findings from the PERL and ACCORD trials. HRV-derived measures from routine ECGs are shown to be strong predictors of rapid kidney function decline in both type 1 and type 2 diabetes, suggesting their potential utility in identifying individuals at high risk for DKD and guiding early preventive interventions.

这篇评论根据 PERL 和 ACCORD 试验的结果,强调了心率变异性 (HRV) 指数在预测糖尿病肾病 (DKD) 进展中的作用。从常规心电图中得出的心率变异指标可有力地预测 1 型和 2 型糖尿病患者肾功能的快速下降,这表明它们在识别 DKD 高危人群和指导早期预防干预方面具有潜在的作用。
{"title":"Heart rate variability indices for predicting cardiorenal outcomes: A lesson from the PERL and ACCORD cohorts","authors":"Kazuhiro Sugimoto","doi":"10.1111/jdi.14333","DOIUrl":"10.1111/jdi.14333","url":null,"abstract":"<p>This commentary highlights the role of heart rate variability (HRV) indices in predicting diabetic kidney disease (DKD) progression, based on findings from the PERL and ACCORD trials. HRV-derived measures from routine ECGs are shown to be strong predictors of rapid kidney function decline in both type 1 and type 2 diabetes, suggesting their potential utility in identifying individuals at high risk for DKD and guiding early preventive interventions.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"5-7"},"PeriodicalIF":3.1,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improvement of heart rate variability after metabolic bariatric surgery in Korean subjects with obesity 韩国肥胖症患者接受代谢减肥手术后心率变异性的改善。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-16 DOI: 10.1111/jdi.14332
Han Na Jang, Young Suk Park, Joon Ho Moon, Sung Hee Choi, Hak Chul Jang, Tae Jung Oh

Introduction

Cardiovascular autonomic neuropathy (CAN) is a chronic complication of diabetes. As obesity is a major risk factor for CAN, we hypothesized that metabolic bariatric surgery (MBS) could improve CAN indices in Korean patients with obesity.

Materials and Methods

Patients who underwent bariatric surgery between February 2020 and June 2022 were prospectively recruited. CAN was conducted once before surgery and again after surgery, using the Ewing method and heart rate variability (HRV) analysis (standard deviation of the NN interval [SDNN], root mean square of successive RR interval difference [RMSSD], and spectral analysis).

Results

A total of 47 patients were included. The mean age was 39.8 ± 8.7 years, 15 (31.9%) were male, and 26 (55.3%) had diabetes. Resting HR before surgery was 81.0 ± 12.3 bpm, which decreased significantly to 68.0 ± 9.3 bpm after surgery (P < 0.001). Changes in HR and BP according to the Valsalva maneuver, postural changes, and handgrip were not significantly different before and after surgery. However, SDNN significantly increased from 25.2 [15.1, 33.5] to 38.0 [25.4, 45.0] ms (P < 0.001), and RMSSD also significantly increased from 17.0 [9.2, 31.8] to 28.2 [15.3, 45.6] ms (P = 0.001). Both low-frequency power (LF) and high-frequency power (HF) increased significantly, and the LF/HF ratio significantly decreased from 2.1 ± 1.6 to 1.3 ± 1.3 (P = 0.010). Loss of weight, fat mass, and lean body mass were independently associated with improving the HRV variables.

Conclusions

MBS improved HRV variables, and these changes were mainly associated with postoperative weight loss.

导言心血管自主神经病变(CAN)是糖尿病的一种慢性并发症。由于肥胖是心血管自主神经病变的主要风险因素,我们假设代谢减肥手术(MBS)可以改善韩国肥胖患者的心血管自主神经病变指数:前瞻性地招募了 2020 年 2 月至 2022 年 6 月期间接受减肥手术的患者。采用尤因法和心率变异性(HRV)分析(NN间期标准偏差[SDNN]、连续RR间期差的均方根[RMSSD]和频谱分析),在术前和术后各进行一次CAN分析:结果:共纳入 47 名患者。平均年龄(39.8±8.7)岁,男性 15 人(31.9%),糖尿病患者 26 人(55.3%)。手术前的静息心率为 81.0 ± 12.3 bpm,手术后明显降低至 68.0 ± 9.3 bpm(P 结论:MBS 改善了心率变异变量,并提高了心率变异性:MBS 改善了心率变异变量,这些变化主要与术后体重减轻有关。
{"title":"Improvement of heart rate variability after metabolic bariatric surgery in Korean subjects with obesity","authors":"Han Na Jang,&nbsp;Young Suk Park,&nbsp;Joon Ho Moon,&nbsp;Sung Hee Choi,&nbsp;Hak Chul Jang,&nbsp;Tae Jung Oh","doi":"10.1111/jdi.14332","DOIUrl":"10.1111/jdi.14332","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Cardiovascular autonomic neuropathy (CAN) is a chronic complication of diabetes. As obesity is a major risk factor for CAN, we hypothesized that metabolic bariatric surgery (MBS) could improve CAN indices in Korean patients with obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Patients who underwent bariatric surgery between February 2020 and June 2022 were prospectively recruited. CAN was conducted once before surgery and again after surgery, using the Ewing method and heart rate variability (HRV) analysis (standard deviation of the NN interval [SDNN], root mean square of successive RR interval difference [RMSSD], and spectral analysis).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 47 patients were included. The mean age was 39.8 ± 8.7 years, 15 (31.9%) were male, and 26 (55.3%) had diabetes. Resting HR before surgery was 81.0 ± 12.3 bpm, which decreased significantly to 68.0 ± 9.3 bpm after surgery (<i>P</i> &lt; 0.001). Changes in HR and BP according to the Valsalva maneuver, postural changes, and handgrip were not significantly different before and after surgery. However, SDNN significantly increased from 25.2 [15.1, 33.5] to 38.0 [25.4, 45.0] ms (<i>P</i> &lt; 0.001), and RMSSD also significantly increased from 17.0 [9.2, 31.8] to 28.2 [15.3, 45.6] ms (<i>P</i> = 0.001). Both low-frequency power (LF) and high-frequency power (HF) increased significantly, and the LF/HF ratio significantly decreased from 2.1 ± 1.6 to 1.3 ± 1.3 (<i>P</i> = 0.010). Loss of weight, fat mass, and lean body mass were independently associated with improving the HRV variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MBS improved HRV variables, and these changes were mainly associated with postoperative weight loss.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1773-1780"},"PeriodicalIF":3.1,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14332","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clustering-based risk stratification of prediabetes populations: Insights from the Taiwan and UK Biobanks 基于聚类的糖尿病前期人群风险分层:来自台湾和英国生物库的启示。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-10 DOI: 10.1111/jdi.14328
Djeane Debora Onthoni, Ying-Erh Chen, Yi-Hsuan Lai, Guo-Hung Li, Yong-Sheng Zhuang, Hong-Ming Lin, Yu-Ping Hsiao, Ade Indra Onthoni, Hung-Yi Chiou, Ren-Hua Chung

Aims/Introduction

This study aimed to identify low- and high-risk diabetes groups within prediabetes populations using data from the Taiwan Biobank (TWB) and UK Biobank (UKB) through a clustering-based Unsupervised Learning (UL) approach, to inform targeted type 2 diabetes (T2D) interventions.

Materials and Methods

Data from TWB and UKB, comprising clinical and genetic information, were analyzed. Prediabetes was defined by glucose thresholds, and incident T2D was identified through follow-up data. K-means clustering was performed on prediabetes participants using significant features determined through logistic regression and LASSO. Cluster stability was assessed using mean Jaccard similarity, silhouette score, and the elbow method.

Results

We identified two stable clusters representing high- and low-risk diabetes groups in both biobanks. The high-risk clusters showed higher diabetes incidence, with 15.7% in TWB and 13.0% in UKB, compared to 7.3% and 9.1% in the low-risk clusters, respectively. Notably, males were predominant in the high-risk groups, constituting 76.6% in TWB and 52.7% in UKB. In TWB, the high-risk group also exhibited significantly higher BMI, fasting glucose, and triglycerides, while UKB showed marginal significance in BMI and other metabolic indicators. Current smoking was significantly associated with increased diabetes risk in the TWB high-risk group (P < 0.001). Kaplan–Meier curves indicated significant differences in diabetes complication incidences between clusters.

Conclusions

UL effectively identified risk-specific groups within prediabetes populations, with high-risk groups strongly associated male gender, higher BMI, smoking, and metabolic markers. Tailored preventive strategies, particularly for young males in Taiwan, are crucial to reducing T2D risk.

目的/简介:本研究旨在通过基于聚类的无监督学习(UL)方法,利用台湾生物样本库(TWB)和英国生物样本库(UKB)的数据,识别糖尿病前期人群中的低风险和高风险糖尿病群体,为有针对性的2型糖尿病(T2D)干预措施提供依据:对来自 TWB 和 UKB 的数据(包括临床和遗传信息)进行了分析。糖尿病前期由血糖阈值定义,T2D事件则通过随访数据确定。利用逻辑回归和LASSO确定的重要特征对糖尿病前期参与者进行K均值聚类。使用平均 Jaccard 相似度、剪影得分和肘法评估聚类的稳定性:结果:我们在两个生物库中发现了代表高危和低危糖尿病群体的两个稳定聚类。高风险群组的糖尿病发病率较高,在 TWB 中为 15.7%,在 UKB 中为 13.0%,而在低风险群组中分别为 7.3%和 9.1%。值得注意的是,男性在高危人群中占主导地位,在 TWB 中占 76.6%,在 UKB 中占 52.7%。在 TWB 中,高风险组的体重指数、空腹血糖和甘油三酯也明显较高,而在 UKB 中,体重指数和其他代谢指标的差异不大。在 TWB 高危人群中,当前吸烟与糖尿病风险的增加有明显相关性(P 结论:UL 能有效识别 TWB 高危人群中的特定风险组:UL 能有效识别糖尿病前期人群中的特定风险组,高风险组与男性性别、较高的体重指数、吸烟和代谢指标密切相关。量身定制的预防策略,尤其是针对台湾年轻男性的策略,对于降低 T2D 风险至关重要。
{"title":"Clustering-based risk stratification of prediabetes populations: Insights from the Taiwan and UK Biobanks","authors":"Djeane Debora Onthoni,&nbsp;Ying-Erh Chen,&nbsp;Yi-Hsuan Lai,&nbsp;Guo-Hung Li,&nbsp;Yong-Sheng Zhuang,&nbsp;Hong-Ming Lin,&nbsp;Yu-Ping Hsiao,&nbsp;Ade Indra Onthoni,&nbsp;Hung-Yi Chiou,&nbsp;Ren-Hua Chung","doi":"10.1111/jdi.14328","DOIUrl":"10.1111/jdi.14328","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>This study aimed to identify low- and high-risk diabetes groups within prediabetes populations using data from the Taiwan Biobank (TWB) and UK Biobank (UKB) through a clustering-based Unsupervised Learning (UL) approach, to inform targeted type 2 diabetes (T2D) interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Data from TWB and UKB, comprising clinical and genetic information, were analyzed. Prediabetes was defined by glucose thresholds, and incident T2D was identified through follow-up data. K-means clustering was performed on prediabetes participants using significant features determined through logistic regression and LASSO. Cluster stability was assessed using mean Jaccard similarity, silhouette score, and the elbow method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified two stable clusters representing high- and low-risk diabetes groups in both biobanks. The high-risk clusters showed higher diabetes incidence, with 15.7% in TWB and 13.0% in UKB, compared to 7.3% and 9.1% in the low-risk clusters, respectively. Notably, males were predominant in the high-risk groups, constituting 76.6% in TWB and 52.7% in UKB. In TWB, the high-risk group also exhibited significantly higher BMI, fasting glucose, and triglycerides, while UKB showed marginal significance in BMI and other metabolic indicators. Current smoking was significantly associated with increased diabetes risk in the TWB high-risk group (<i>P</i> &lt; 0.001). Kaplan–Meier curves indicated significant differences in diabetes complication incidences between clusters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>UL effectively identified risk-specific groups within prediabetes populations, with high-risk groups strongly associated male gender, higher BMI, smoking, and metabolic markers. Tailored preventive strategies, particularly for young males in Taiwan, are crucial to reducing T2D risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"25-35"},"PeriodicalIF":3.1,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142454284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Causes of death in Japanese patients with diabetes based on the results of a survey of 68,555 cases during 2011–2020: Committee report on causes of death in diabetes mellitus, Japan Diabetes Society (English version) 根据 2011-2020 年间对 68 555 个病例的调查结果得出的日本糖尿病患者死亡原因:糖尿病死亡原因委员会报告》,日本糖尿病学会(英文版)。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-04 DOI: 10.1111/jdi.14232
Jiro Nakamura, Narihito Yoshioka, Hideki Katagiri, Kohjiro Ueki, Toshimasa Yamauchi, Nobuya Inagaki, Yukio Tanizawa, Eiichi Araki, Takeo Nakayama, Hideki Kamiya
<p>The principal causes of death among 68,555 patients with diabetes and 164,621 patients without diabetes who died in 208 hospitals throughout Japan between 2011 and 2020 were determined based on a survey of hospital records. The most frequent cause of death in patients with diabetes was malignant neoplasms (38.9%) (lung 7.8%, pancreas 6.5%, liver 4.1%), followed, in order of descending frequency, by infectious diseases (17.0%) and then vascular diseases (10.9%) (cerebrovascular diseases 5.2%, ischemic heart diseases 3.5%, renal failure 2.3%). The proportion of deaths from malignant neoplasms and vascular diseases has trended upward and downward, respectively. Almost all deaths from ischemic heart diseases were due to myocardial infarction, and the proportion of deaths from heart diseases other than ischemic heart diseases was relatively high (9.0%), with most cases due to heart failure. Diabetic coma associated with hyperglycemia accounted for only 0.3% of deaths. The proportion of deaths from malignant neoplasms, infectious diseases, renal failure, ischemic heart diseases, and heart failure was significantly higher in patients with diabetes than in those without diabetes, and the proportion of deaths from cerebrovascular diseases was significantly lower in patients with diabetes. With regard to the relationship between the age and cause of death in patients with diabetes, malignant neoplasms were the most frequent cause of death in all age groups, and the incidence was around 50% for those in their 50s and 60s. The incidence of death due to infectious diseases was highest in patients older than their 70s. The incidence of death due to vascular diseases for patients in their 40s and 50s was higher than that due to infectious diseases. The highest incidence of death due to ischemic heart diseases was observed for patients in their 40s, and that due to renal failure and heart failure in patients older than their 70s. Compared with patients without diabetes, patients with diabetes demonstrated a higher incidence of death due to pancreatic cancer, infectious diseases, renal failure, ischemic heart diseases, and heart failure, and a lower incidence of death due to cerebrovascular diseases in all age groups. The average age at death of patients with diabetes was 74.4 years old in men and 77.4 years old in women, which were lower than the average lifespan of the Japanese general population in 2020 by 7.2 and 10.3 years, respectively. However, these differences were smaller than in previous surveys. The average age at death due to all causes, especially due to ischemic heart diseases, cerebrovascular diseases, heart failure, infectious diseases, and diabetic coma, was lower in patients with ‘poorer’ glycemic control than in those with ‘better’ glycemic control. In the total survey population, the average age at death of patients with diabetes was significantly higher than that of patients without diabetes. The average age at death due to malignant neop
根据对医院记录的调查,确定了 2011 年至 2020 年期间在日本全国 208 家医院死亡的 68,555 名糖尿病患者和 164,621 名非糖尿病患者的主要死因。糖尿病患者最常见的死因是恶性肿瘤(38.9%)(肺部 7.8%、胰腺 6.5%、肝脏 4.1%),其次依次是传染病(17.0%)和血管疾病(10.9%)(脑血管疾病 5.2%、缺血性心脏病 3.5%、肾功能衰竭 2.3%)。恶性肿瘤和血管疾病的死亡比例分别呈上升和下降趋势。几乎所有死于缺血性心脏病的病例都是由于心肌梗死,而死于缺血性心脏病以外的心脏病的比例相对较高(9.0%),其中大多数病例是由于心力衰竭。与高血糖相关的糖尿病昏迷仅占死亡人数的 0.3%。糖尿病患者死于恶性肿瘤、传染病、肾功能衰竭、缺血性心脏病和心力衰竭的比例明显高于非糖尿病患者,而糖尿病患者死于脑血管疾病的比例明显低于非糖尿病患者。关于糖尿病患者的年龄与死因之间的关系,恶性肿瘤是所有年龄组中最常见的死因,50 至 60 岁年龄组的发病率约为 50%。在 70 岁以上的患者中,传染病致死率最高。四五十岁患者因血管疾病死亡的发生率高于因传染病死亡的发生率。40 多岁患者因缺血性心脏病死亡的比例最高,70 多岁患者因肾功能衰竭和心力衰竭死亡的比例最高。与非糖尿病患者相比,糖尿病患者因胰腺癌、感染性疾病、肾功能衰竭、缺血性心脏病和心力衰竭死亡的发生率较高,而在所有年龄组中因脑血管疾病死亡的发生率较低。糖尿病患者的平均死亡年龄男性为 74.4 岁,女性为 77.4 岁,分别比 2020 年日本普通人口的平均寿命低 7.2 岁和 10.3 岁。不过,这些差异比以往的调查要小。血糖控制 "较差 "的患者死于各种原因的平均年龄低于血糖控制 "较好 "的患者,尤其是缺血性心脏病、脑血管疾病、心力衰竭、感染性疾病和糖尿病昏迷。在所有调查人群中,糖尿病患者的平均死亡年龄明显高于非糖尿病患者。糖尿病患者死于恶性肿瘤和脑血管疾病的平均年龄高于非糖尿病患者,而糖尿病患者死于肾功能衰竭、缺血性心脏病和传染病的平均年龄低于非糖尿病患者。
{"title":"Causes of death in Japanese patients with diabetes based on the results of a survey of 68,555 cases during 2011–2020: Committee report on causes of death in diabetes mellitus, Japan Diabetes Society (English version)","authors":"Jiro Nakamura,&nbsp;Narihito Yoshioka,&nbsp;Hideki Katagiri,&nbsp;Kohjiro Ueki,&nbsp;Toshimasa Yamauchi,&nbsp;Nobuya Inagaki,&nbsp;Yukio Tanizawa,&nbsp;Eiichi Araki,&nbsp;Takeo Nakayama,&nbsp;Hideki Kamiya","doi":"10.1111/jdi.14232","DOIUrl":"10.1111/jdi.14232","url":null,"abstract":"&lt;p&gt;The principal causes of death among 68,555 patients with diabetes and 164,621 patients without diabetes who died in 208 hospitals throughout Japan between 2011 and 2020 were determined based on a survey of hospital records. The most frequent cause of death in patients with diabetes was malignant neoplasms (38.9%) (lung 7.8%, pancreas 6.5%, liver 4.1%), followed, in order of descending frequency, by infectious diseases (17.0%) and then vascular diseases (10.9%) (cerebrovascular diseases 5.2%, ischemic heart diseases 3.5%, renal failure 2.3%). The proportion of deaths from malignant neoplasms and vascular diseases has trended upward and downward, respectively. Almost all deaths from ischemic heart diseases were due to myocardial infarction, and the proportion of deaths from heart diseases other than ischemic heart diseases was relatively high (9.0%), with most cases due to heart failure. Diabetic coma associated with hyperglycemia accounted for only 0.3% of deaths. The proportion of deaths from malignant neoplasms, infectious diseases, renal failure, ischemic heart diseases, and heart failure was significantly higher in patients with diabetes than in those without diabetes, and the proportion of deaths from cerebrovascular diseases was significantly lower in patients with diabetes. With regard to the relationship between the age and cause of death in patients with diabetes, malignant neoplasms were the most frequent cause of death in all age groups, and the incidence was around 50% for those in their 50s and 60s. The incidence of death due to infectious diseases was highest in patients older than their 70s. The incidence of death due to vascular diseases for patients in their 40s and 50s was higher than that due to infectious diseases. The highest incidence of death due to ischemic heart diseases was observed for patients in their 40s, and that due to renal failure and heart failure in patients older than their 70s. Compared with patients without diabetes, patients with diabetes demonstrated a higher incidence of death due to pancreatic cancer, infectious diseases, renal failure, ischemic heart diseases, and heart failure, and a lower incidence of death due to cerebrovascular diseases in all age groups. The average age at death of patients with diabetes was 74.4 years old in men and 77.4 years old in women, which were lower than the average lifespan of the Japanese general population in 2020 by 7.2 and 10.3 years, respectively. However, these differences were smaller than in previous surveys. The average age at death due to all causes, especially due to ischemic heart diseases, cerebrovascular diseases, heart failure, infectious diseases, and diabetic coma, was lower in patients with ‘poorer’ glycemic control than in those with ‘better’ glycemic control. In the total survey population, the average age at death of patients with diabetes was significantly higher than that of patients without diabetes. The average age at death due to malignant neop","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1821-1837"},"PeriodicalIF":3.1,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14232","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The roles of output clock genes in regulating glucose metabolism 输出时钟基因在调节葡萄糖代谢中的作用。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-03 DOI: 10.1111/jdi.14295
Akihiko Taguchi, Yasuharu Ohta, Yuko Nagao, Yukio Tanizawa
<p>Circadian rhythm is an endogenous autonomous oscillator of physiological activities resulting in 24 h day/night cycles. This rhythm is regarded as a system regulating organisms allowing them to carry out efficient biological activities during the day–night cycle. In humans, the rhythm is set at 24 h and 11 ± 16 min, which is slightly longer than the day rhythm (24 h). Therefore, when living in a dark room, the waking time is slightly delayed each day<span><sup>1</sup></span>.</p><p>The invention of electric light revolutionized society, with humans now able to work at night, including shift work, and such disruption of the circadian rhythm reportedly increases insulin resistance, as well as raising the risks of type 2 diabetes and cardiovascular diseases<span><sup>2, 3</sup></span>.</p><p>In humans, the center of the circadian rhythm is located in the suprachiasmatic nucleus, and the rhythm is generated by a set of genes known as clock genes. The following molecular mechanism generates circadian rhythms: first, the heterodimer of CLOCK-BMAL1, a set of the core clock gene products, binds to the promoters of the <i>Per</i> and <i>Cry</i> clock genes, thereby activating both <i>Per</i> and <i>Cry</i> transcription. The translated PER and CRY then suppress CLOCK-BMAL1 transcriptional activity through a negative feedback mechanism, and this loop cycles once every 24 h to generate a circadian rhythm (Figure 1). The genes involved in this circuit are referred to as ‘core clock genes’.</p><p>Core clock genes such as <i>Bmal1</i> and <i>Clock</i> generate circadian rhythms by regulating a group of genes with E-box sequences that provide a rhythm underlying cellular functions. For example, in pancreatic islet β-cells, BMAL1 and CLOCK directly regulate a group of genes related to insulin secretion, generating a distinct circadian rhythm for insulin secretion<span><sup>4</sup></span>. In addition to these direct regulatory factors, another set of transcription factors, referred to as clock output genes, transmit the signals from core clock genes to downstream effector genes. Clock output genes include DBP, TEF, HLF, and E4BP4. We and others have recently conducted rigorous studies of their effects on metabolism (Table 1). Herein, we discuss the roles of these clock output genes, focusing on glucose metabolism.</p><p>Future research is anticipated to reveal the mechanisms underlying peripheral clock gene regulation, opening the way to the development of drugs targeting these genes without disrupting the central circadian rhythm. While drugs influencing core clock genes have shown metabolic benefits in mice, their use in patients with metabolic diseases requires further investigation aimed at minimizing any adverse effects on the central biological clock.</p><p>Yukio Tanizawa is an Editorial Board member of <i>Journal of Diabetes Investigation</i> and a co-author of this article. To minimize bias, he was excluded from all editorial decision-making related t
昼夜节律是导致24小时昼夜循环的生理活动的内源性自主振荡器。这种节律被认为是一种调节生物体的系统,允许它们在昼夜循环中进行有效的生物活动。人类的昼夜节律设定在24小时11±16分钟,比白天的昼夜节律(24小时)稍长。因此,当生活在黑暗的房间里时,每天醒来的时间会稍微延迟1。电灯的发明彻底改变了社会,人类现在可以在晚上工作,包括轮班工作,据报道,这种昼夜节律的破坏增加了胰岛素抵抗,也增加了2型糖尿病和心血管疾病的风险。在人类中,昼夜节律的中心位于视交叉上核,节律是由一组被称为时钟基因的基因产生的。产生昼夜节律的分子机制如下:首先,一组核心时钟基因产物clock - bmal1的异二聚体与Per和Cry时钟基因的启动子结合,从而激活Per和Cry的转录。翻译后的PER和CRY通过负反馈机制抑制clock - bmal1的转录活性,该循环每24小时循环一次,产生昼夜节律(图1)。参与该回路的基因被称为“核心时钟基因”。核心时钟基因,如Bmal1和clock,通过调节一组具有E-box序列的基因来产生昼夜节律,这些基因提供了细胞功能的节律。例如,在胰岛β细胞中,BMAL1和CLOCK直接调节一组与胰岛素分泌相关的基因,产生胰岛素分泌的独特昼夜节律4。除了这些直接调控因子外,还有一组转录因子,称为时钟输出基因,将核心时钟基因的信号传递给下游效应基因。时钟输出基因包括DBP、TEF、HLF和E4BP4。我们和其他人最近对它们对代谢的影响进行了严格的研究(表1)。在这里,我们讨论了这些时钟输出基因的作用,重点是葡萄糖代谢。未来的研究有望揭示外周时钟基因调控的机制,为开发靶向这些基因的药物开辟道路,同时不破坏中心昼夜节律。虽然影响核心生物钟基因的药物在小鼠中显示出代谢益处,但它们在代谢性疾病患者中的应用需要进一步研究,以尽量减少对中枢生物钟的任何不利影响。Yukio Tanizawa是《糖尿病调查杂志》的编辑委员会成员,也是本文的合著者。为了尽量减少偏倚,他被排除在所有与接受这篇文章发表相关的编辑决策之外。
{"title":"The roles of output clock genes in regulating glucose metabolism","authors":"Akihiko Taguchi,&nbsp;Yasuharu Ohta,&nbsp;Yuko Nagao,&nbsp;Yukio Tanizawa","doi":"10.1111/jdi.14295","DOIUrl":"10.1111/jdi.14295","url":null,"abstract":"&lt;p&gt;Circadian rhythm is an endogenous autonomous oscillator of physiological activities resulting in 24 h day/night cycles. This rhythm is regarded as a system regulating organisms allowing them to carry out efficient biological activities during the day–night cycle. In humans, the rhythm is set at 24 h and 11 ± 16 min, which is slightly longer than the day rhythm (24 h). Therefore, when living in a dark room, the waking time is slightly delayed each day&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;The invention of electric light revolutionized society, with humans now able to work at night, including shift work, and such disruption of the circadian rhythm reportedly increases insulin resistance, as well as raising the risks of type 2 diabetes and cardiovascular diseases&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;In humans, the center of the circadian rhythm is located in the suprachiasmatic nucleus, and the rhythm is generated by a set of genes known as clock genes. The following molecular mechanism generates circadian rhythms: first, the heterodimer of CLOCK-BMAL1, a set of the core clock gene products, binds to the promoters of the &lt;i&gt;Per&lt;/i&gt; and &lt;i&gt;Cry&lt;/i&gt; clock genes, thereby activating both &lt;i&gt;Per&lt;/i&gt; and &lt;i&gt;Cry&lt;/i&gt; transcription. The translated PER and CRY then suppress CLOCK-BMAL1 transcriptional activity through a negative feedback mechanism, and this loop cycles once every 24 h to generate a circadian rhythm (Figure 1). The genes involved in this circuit are referred to as ‘core clock genes’.&lt;/p&gt;&lt;p&gt;Core clock genes such as &lt;i&gt;Bmal1&lt;/i&gt; and &lt;i&gt;Clock&lt;/i&gt; generate circadian rhythms by regulating a group of genes with E-box sequences that provide a rhythm underlying cellular functions. For example, in pancreatic islet β-cells, BMAL1 and CLOCK directly regulate a group of genes related to insulin secretion, generating a distinct circadian rhythm for insulin secretion&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;. In addition to these direct regulatory factors, another set of transcription factors, referred to as clock output genes, transmit the signals from core clock genes to downstream effector genes. Clock output genes include DBP, TEF, HLF, and E4BP4. We and others have recently conducted rigorous studies of their effects on metabolism (Table 1). Herein, we discuss the roles of these clock output genes, focusing on glucose metabolism.&lt;/p&gt;&lt;p&gt;Future research is anticipated to reveal the mechanisms underlying peripheral clock gene regulation, opening the way to the development of drugs targeting these genes without disrupting the central circadian rhythm. While drugs influencing core clock genes have shown metabolic benefits in mice, their use in patients with metabolic diseases requires further investigation aimed at minimizing any adverse effects on the central biological clock.&lt;/p&gt;&lt;p&gt;Yukio Tanizawa is an Editorial Board member of &lt;i&gt;Journal of Diabetes Investigation&lt;/i&gt; and a co-author of this article. To minimize bias, he was excluded from all editorial decision-making related t","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1707-1710"},"PeriodicalIF":3.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14295","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Ulaanbaatar agreement: Revising diabetes terminology in Asia to combat stigma 乌兰巴托协议:修订亚洲糖尿病术语,消除偏见。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-03 DOI: 10.1111/jdi.14330
Yutaka Seino, Daisuke Yabe, Kazuhiro Tsumura, Chien-Ning Huang, So Hun Kim, Weiping Jia, Altaisaikhan Khasag, Takashi Kadowaki

Many Asian countries, including Japan, China, and South Korea, continue to use terms that reference sugar and urine, contributing to ongoing stigma, while most of the rest of the world seem to use terms related to the original “Diabetes,” meaning “to pass through.” The 16th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD) was held, featuring a pivotal joint symposium organized by AASD and the Japanese Association of Diabetes Education and Care where an in-depth discussion was carried out on diabetes-related terminology across various Asian countries and regions, with a particular focus on the stigma associated with existing terms. The symposium participants reached a consensus on the necessity of revising the stigmatizing diabetes terminology across Asia and agreed to continue discussions and monitor progress at the 17th AASD Scientific Meeting, scheduled to be held in 2025.

包括日本、中国和韩国在内的许多亚洲国家仍在使用与糖和尿有关的术语,这导致了持续的污名化,而世界上其他大多数国家似乎都在使用与 "糖尿病 "原意有关的术语,意为 "通过"。在亚洲糖尿病研究协会(AASD)第 16 届科学会议上,亚洲糖尿病研究协会和日本糖尿病教育与护理协会联合举办了一场重要的研讨会,就亚洲各国和地区与糖尿病相关的术语进行了深入讨论,尤其关注与现有术语相关的污名化问题。研讨会与会者达成共识,认为有必要在整个亚洲范围内修订糖尿病污名化术语,并同意在定于 2025 年举行的第 17 届亚洲糖尿病学会科学会议上继续讨论并监测进展情况。
{"title":"The Ulaanbaatar agreement: Revising diabetes terminology in Asia to combat stigma","authors":"Yutaka Seino,&nbsp;Daisuke Yabe,&nbsp;Kazuhiro Tsumura,&nbsp;Chien-Ning Huang,&nbsp;So Hun Kim,&nbsp;Weiping Jia,&nbsp;Altaisaikhan Khasag,&nbsp;Takashi Kadowaki","doi":"10.1111/jdi.14330","DOIUrl":"10.1111/jdi.14330","url":null,"abstract":"<p>Many Asian countries, including Japan, China, and South Korea, continue to use terms that reference sugar and urine, contributing to ongoing stigma, while most of the rest of the world seem to use terms related to the original “Diabetes,” meaning “to pass through.” The 16th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD) was held, featuring a pivotal joint symposium organized by AASD and the Japanese Association of Diabetes Education and Care where an in-depth discussion was carried out on diabetes-related terminology across various Asian countries and regions, with a particular focus on the stigma associated with existing terms. The symposium participants reached a consensus on the necessity of revising the stigmatizing diabetes terminology across Asia and agreed to continue discussions and monitor progress at the 17th AASD Scientific Meeting, scheduled to be held in 2025.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 11","pages":"1533-1536"},"PeriodicalIF":3.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-carbohydrate diets in East Asians with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials 东亚 2 型糖尿病患者的低碳水化合物饮食:随机对照试验的系统回顾和荟萃分析。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-03 DOI: 10.1111/jdi.14326
Junya Hironaka, Masahide Hamaguchi, Takahiro Ichikawa, Hanako Nakajima, Takuro Okamura, Saori Majima, Takafumi Senmaru, Hiroshi Okada, Emi Ushigome, Naoko Nakanishi, Erina Joo, Kenichiro Shide, Michiaki Fukui

Aims

Despite the reported success of low-carbohydrate diets in improving glycemic control in the Western countries, no studies have investigated the effects of such diets in Asians. We aimed to conduct a systematic review and meta-analysis of randomized controlled trials to examine the effects of low-carbohydrate diets on glycemic control in East Asian adults.

Materials and Methods

We systematically searched the PubMed, Cochrane Library, and Embase databases from inception to June 28, 2023, to identify randomized controlled trials examining the efficacy of low-carbohydrate diets in patients with type 2 diabetes (PROSPERO number CRD 42023453007). The primary outcome was the difference in glycated hemoglobin levels between the low-carbohydrate diet and control groups. The secondary outcome was the difference in body mass index, fasting blood glucose level, blood pressure, and lipid profile.

Results

Six randomized controlled trials met the eligibility criteria. The study duration ranged from 3 to 18 months, with five studies conducted within 6 months. The results showed that low-carbohydrate diets were more beneficial in lowering glycated hemoglobin levels and body mass index than control diets. The risk of bias for the six studies was minimal for two and moderate for four. The heterogeneity among the studies was low.

Conclusions

Low-carbohydrate diets improved glycated hemoglobin levels and body mass index in East Asians compared with control diets. Therefore, carbohydrate restriction may be effective for glycemic management in East Asians with type 2 diabetes for at least 6 months.

目的:尽管低碳水化合物膳食在西方国家成功改善了血糖控制,但尚未有研究调查此类膳食对亚洲人的影响。我们旨在对随机对照试验进行系统回顾和荟萃分析,以研究低碳水化合物饮食对东亚成年人血糖控制的影响:我们系统地检索了 PubMed、Cochrane Library 和 Embase 数据库(从开始到 2023 年 6 月 28 日),以确定研究低碳水化合物饮食对 2 型糖尿病患者疗效的随机对照试验(PROSPERO 编号 CRD 42023453007)。主要结果是低碳水化合物饮食组和对照组之间糖化血红蛋白水平的差异。次要结果是体重指数、空腹血糖水平、血压和血脂状况的差异:结果:六项随机对照试验符合资格标准。研究持续时间从 3 个月到 18 个月不等,其中 5 项研究在 6 个月内进行。结果显示,与对照饮食相比,低碳水化合物饮食更有利于降低糖化血红蛋白水平和体重指数。六项研究中,两项研究的偏倚风险极小,四项研究的偏倚风险中等。研究的异质性较低:结论:与对照饮食相比,低碳水化合物饮食可改善东亚人的糖化血红蛋白水平和体重指数。因此,在至少 6 个月的时间内,限制碳水化合物可能会有效控制东亚人 2 型糖尿病患者的血糖。
{"title":"Low-carbohydrate diets in East Asians with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","authors":"Junya Hironaka,&nbsp;Masahide Hamaguchi,&nbsp;Takahiro Ichikawa,&nbsp;Hanako Nakajima,&nbsp;Takuro Okamura,&nbsp;Saori Majima,&nbsp;Takafumi Senmaru,&nbsp;Hiroshi Okada,&nbsp;Emi Ushigome,&nbsp;Naoko Nakanishi,&nbsp;Erina Joo,&nbsp;Kenichiro Shide,&nbsp;Michiaki Fukui","doi":"10.1111/jdi.14326","DOIUrl":"10.1111/jdi.14326","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Despite the reported success of low-carbohydrate diets in improving glycemic control in the Western countries, no studies have investigated the effects of such diets in Asians. We aimed to conduct a systematic review and meta-analysis of randomized controlled trials to examine the effects of low-carbohydrate diets on glycemic control in East Asian adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We systematically searched the PubMed, Cochrane Library, and Embase databases from inception to June 28, 2023, to identify randomized controlled trials examining the efficacy of low-carbohydrate diets in patients with type 2 diabetes (PROSPERO number CRD 42023453007). The primary outcome was the difference in glycated hemoglobin levels between the low-carbohydrate diet and control groups. The secondary outcome was the difference in body mass index, fasting blood glucose level, blood pressure, and lipid profile.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Six randomized controlled trials met the eligibility criteria. The study duration ranged from 3 to 18 months, with five studies conducted within 6 months. The results showed that low-carbohydrate diets were more beneficial in lowering glycated hemoglobin levels and body mass index than control diets. The risk of bias for the six studies was minimal for two and moderate for four. The heterogeneity among the studies was low.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Low-carbohydrate diets improved glycated hemoglobin levels and body mass index in East Asians compared with control diets. Therefore, carbohydrate restriction may be effective for glycemic management in East Asians with type 2 diabetes for at least 6 months.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1753-1762"},"PeriodicalIF":3.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142363624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noncoding RNAs and diabetic kidney disease 非编码 RNA 与糖尿病肾病
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-10-03 DOI: 10.1111/jdi.14331
Jun Wada

In both human clinical and animal experimental studies, the altered expression of regulatory RNAs such as miRNAs, lncRNAs, and circRNAs are reported in diabetes and its complications by investigating various samples of serum, plasma, whole blood, and tissues. These identified ncRNAs are candidates for the disease diagnostic markers, prognostic markers, and also therapeutic targets. In the updates, the recently published ncRNAs involved in the onset and progression of DKD are discussed.

在人类临床和动物实验研究中,通过对各种血清、血浆、全血和组织样本的研究,发现了糖尿病及其并发症中调控 RNA(如 miRNA、lncRNA 和 circRNA)表达的改变。这些已发现的 ncRNA 是疾病诊断标志物、预后标志物和治疗靶点的候选者。本报告将讨论最近发表的与 DKD 发病和进展有关的 ncRNAs。
{"title":"Noncoding RNAs and diabetic kidney disease","authors":"Jun Wada","doi":"10.1111/jdi.14331","DOIUrl":"10.1111/jdi.14331","url":null,"abstract":"<p>In both human clinical and animal experimental studies, the altered expression of regulatory RNAs such as miRNAs, lncRNAs, and circRNAs are reported in diabetes and its complications by investigating various samples of serum, plasma, whole blood, and tissues. These identified ncRNAs are candidates for the disease diagnostic markers, prognostic markers, and also therapeutic targets. In the updates, the recently published ncRNAs involved in the onset and progression of DKD are discussed.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 1","pages":"8-9"},"PeriodicalIF":3.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation of glucose and energy metabolism through actions of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide 通过胰高血糖素样肽-1 和葡萄糖依赖性促胰岛素多肽的作用调节葡萄糖和能量代谢。
IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-30 DOI: 10.1111/jdi.14305
Yasuo Zenimaru, Norio Harada

There are several physiological and pharmacological actions of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide for the regulation of blood glucose and bodyweight.

胰高血糖素样肽-1 和葡萄糖依赖性促胰岛素多肽/胃抑制多肽在调节血糖和体重方面具有多种生理和药理作用。
{"title":"Regulation of glucose and energy metabolism through actions of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","authors":"Yasuo Zenimaru,&nbsp;Norio Harada","doi":"10.1111/jdi.14305","DOIUrl":"10.1111/jdi.14305","url":null,"abstract":"<p>There are several physiological and pharmacological actions of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide for the regulation of blood glucose and bodyweight.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1725-1726"},"PeriodicalIF":3.1,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14305","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Diabetes Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1